Skip to the page

Data / Drug companies / Amneal Pharmaceuticals LLC

Amneal Pharmaceuticals LLC: 130 products in the FDA NDC directory, labeler code 70121

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Amneal Pharmaceuticals LLC (labeler code 70121) lists 130 products in the FDA National Drug Code Directory, covering 63 finished drugs by generic name. By type: 130 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on September 23, 2026.

The request: Watch Amneal Pharmaceuticals LLC (FDA labeler code 70121): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
70121
Products in commercial distribution
130
Packages
163
Finished drugs by generic name
63
Prescription products
130
Over the counter products
0
Flagged as original packager
124 of 124 products that carry the flag
Started marketing in the last 12 months
4
Products with a marketing end date set
4
Earliest marketing start
May 9, 2016
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)10480%
New drug applications (NDA)1713.1%
Biologics (BLA)96.9%

Products by type

TypeProductsShare
Prescription drugs130100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Injection4836.9%
Injection, solution3728.5%
Injection, suspension1612.3%
Kit107.7%
Injection, powder, lyophilized, for solution107.7%
Injection, powder, for solution75.4%
Injection, solution, concentrate10.8%
Injection, emulsion10.8%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Lanreotide acetate70121-2517InjectionGeneric drugs (ANDA)September 23, 2026
Romidepsin70121-2250Injection, solution, concentrateGeneric drugs (ANDA)June 2, 2026
Boncresa70121-2702Injection, solutionBiologics (BLA)December 23, 2025
Oziltus70121-2701Injection, solutionBiologics (BLA)December 23, 2025
Phytonadione70121-1682Injection, emulsionGeneric drugs (ANDA)November 4, 2025
Epinephrine70121-1660InjectionGeneric drugs (ANDA)October 14, 2025
Labetalol hydrochloride70121-2428Injection, solutionGeneric drugs (ANDA)October 2, 2025
Calcitonin salmon70121-1650Injection, solutionGeneric drugs (ANDA)September 26, 2025
Risperidone70121-2628KitGeneric drugs (ANDA)September 8, 2025
Risperidone70121-2627KitGeneric drugs (ANDA)September 8, 2025
Risperidone70121-2626KitGeneric drugs (ANDA)September 8, 2025
Risperidone70121-2625KitGeneric drugs (ANDA)September 8, 2025
Fulvestrant70121-1463Injection, solutionGeneric drugs (ANDA)June 3, 2025
Tepadina70121-2749Injection, powder, lyophilized, for solutionNew drug applications (NDA)April 18, 2025
Tepadina70121-1687Injection, powder, lyophilized, for solutionNew drug applications (NDA)April 18, 2025
Methylene blue70121-2716Injection, solutionGeneric drugs (ANDA)March 3, 2025
Methylene blue70121-2715Injection, solutionGeneric drugs (ANDA)March 3, 2025
Doxycycline70121-1616Injection, powder, lyophilized, for solutionGeneric drugs (ANDA)December 6, 2024
Exenatide70121-1686InjectionGeneric drugs (ANDA)November 22, 2024
Exenatide70121-1685InjectionGeneric drugs (ANDA)November 22, 2024
Boruzu70121-2484InjectionNew drug applications (NDA)September 27, 2024
Potassium phosphates70121-1722InjectionNew drug applications (NDA)July 30, 2024
Calcium chloride70121-2309Injection, solutionGeneric drugs (ANDA)July 17, 2024
Calcium chloride70121-2308Injection, solutionGeneric drugs (ANDA)July 17, 2024
Focinvez70121-2631InjectionNew drug applications (NDA)June 1, 2024

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.